Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Jade Biosciences, Inc. (NASDAQ:JBIO) have been given a consensus recommendation of “Moderate Buy” by the ten analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have issued a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $47.1250.

A number of analysts have commented on the stock. Guggenheim reiterated a “buy” rating and issued a $47.00 price target on shares of Jade Biosciences in a research note on Tuesday, June 2nd. Stifel Nicolaus set a $40.00 target price on shares of Jade Biosciences in a research note on Friday, March 6th. Jefferies Financial Group restated a “buy” rating on shares of Jade Biosciences in a research note on Monday, June 1st. HC Wainwright raised their target price on shares of Jade Biosciences from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, June 1st. Finally, BTIG Research raised their target price on shares of Jade Biosciences from $39.00 to $74.00 and gave the stock a “buy” rating in a research note on Monday, June 1st.

Institutional Trading of Jade Biosciences

Hedge funds have recently modified their holdings of the stock. Legal & General Group Plc acquired a new stake in shares of Jade Biosciences during the 2nd quarter worth about $29,000. Russell Investments Group Ltd. bought a new stake in shares of Jade Biosciences in the second quarter valued at about $31,000. BNP Paribas Financial Markets bought a new stake in shares of Jade Biosciences in the second quarter valued at about $32,000. California State Teachers Retirement System boosted its position in shares of Jade Biosciences by 40.3% in the fourth quarter. California State Teachers Retirement System now owns 2,850 shares of the company’s stock valued at $44,000 after acquiring an additional 819 shares during the period. Finally, Group One Trading LLC boosted its position in shares of Jade Biosciences by 122.9% in the fourth quarter. Group One Trading LLC now owns 4,195 shares of the company’s stock valued at $65,000 after acquiring an additional 22,527 shares during the period.

Jade Biosciences Price Performance

Shares of JBIO stock opened at $16.82 on Tuesday. The stock has a market cap of $830.24 million, a P/E ratio of -8.33 and a beta of 1.44. The company has a fifty day moving average price of $21.02 and a two-hundred day moving average price of $16.91. Jade Biosciences has a one year low of $6.67 and a one year high of $28.00.

Jade Biosciences (NASDAQ:JBIO) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.05). As a group, equities research analysts anticipate that Jade Biosciences will post -2.54 EPS for the current fiscal year.

About Jade Biosciences

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.